Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Acta Neurochirurgica
Published in: Acta Neurochirurgica 3/2019

01-03-2019 | Meningioma | Case Report - Tumor - Meningioma

Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report

Authors: Pierre-Olivier Champagne, Thibault Passeri, Sebastien Froelich

Published in: Acta Neurochirurgica | Issue 3/2019

Login to get access

Abstract

Cyproterone acetate (CPA) is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. Nomegestrol acetate (NOMAC) is a widely used progestin-like drug that could be suggested as an alternative for patients taking CPA. We report a case of CPA-related meningioma for which relay from CPA to NOMAC led to further tumor growth and cessation of NOMAC-induced tumor shrinkage. We suggest NOMAC can have a similar effect than CPA on meningiomas. The use of NOMAC as replacement for CPA in the presence of a meningioma should be discouraged until further evidence becomes available on the role of NOMAC in such instances.
Literature
1.
Gil M, Oliva B, Timoner J, Macia MA, Bryant V, de Abajo FJ (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 72:965–968CrossRefPubMedPubMedCentral
2.
Goncalves AM, Page P, Domigo V, Meder JF, Oppenheim C (2010) Abrupt regression of a meningioma after discontinuation of cyproterone treatment. AJNR Am J Neuroradiol 31:1504–1505CrossRefPubMed
3.
Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S (2015) Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir 157:1741–1746CrossRefPubMed
4.
Huang Q, Chen X, Zhu Y, Cao L, Riviere JE (2015) Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. Eur J Drug Metab Pharmacokinet 40:435–442CrossRefPubMed
5.
Yang LP, Plosker GL (2012) Nomegestrol acetate/estradiol: in oral contraception. Drugs 72:1917–1928CrossRefPubMed
6.
Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neuro-Oncol 99:307–314CrossRef
7.
O’Shea T, Crowley RK, Farrell M, MacNally S, Govender P, Feeney J, Gibney J, Sherlock M (2016) Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep 2016:16–0054PubMedPubMedCentral
8.
Heijboer AC, Netelenbos JC, Blankenstein MA (2009) Meningioma in untreated congenital adrenal hyperplasia: a relationship? J Neuro-Oncol 92:223–225CrossRef
9.
Li X, Zhao J (2009) Intracranial meningiomas of childhood and adolescence: report of 34 cases with follow-up. Childs Nerv Syst 25:1411–1417CrossRef
10.
Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848–853CrossRefPubMed
11.
Seliger C, Meier CR, Becker C, Jick SS, Proescholdt M, Bogdahn U, Hau P, Leitzmann MF (2017) Metabolic syndrome in relation to risk of meningioma. Oncotarget 8:2284–2292CrossRefPubMed
12.
13.
Koper JW, Lamberts SW (1994) Meningiomas, epidermal growth factor and progesterone. Hum Reprod (Oxford, England) 9(Suppl 1):190–194CrossRef
14.
Guay DR (2009) Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther 31:1–31CrossRefPubMed
15.
Neumann F, Berswordt-Wallrabe RV, Elger W, Steinbeck H, Hahn JD, Kramer M (1970) Aspects of androgen-dependent events as studied by antiandrogens. Recent Prog Horm Res 26:337–410PubMed
16.
Froelich S, Dali-Youcef N, Boyer P, Kehrli P, Maitrot D, Auwerx J (2008) Does cyproterone acetate promote multiple meningiomas? 10th European Congress of Endocrinology, vol 16 Berlin, 158
17.
Lello S (2010) Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs 70:541–559CrossRefPubMed
18.
Mueck AO, Sitruk-Ware R (2011) Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 76:531–539CrossRefPubMed
19.
Durmaz R, Deliorman S, Isiksoy S, Uyar R, Tel E (1999) Luteinizing hormone releasing hormone increases proliferation of meningioma cells in vitro. Arch Physiol Biochem 107:286–291PubMed
20.
Lee KL, Terris MK (2003) Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology 62:351PubMed
21.
Cottin V, Vukusic S, Jouanneau E, Lazor R, Cordier J-F (2004) Should patients with lymphangioleiomyomatosis undergo screening for meningioma? Eur Respir J 24:888–889CrossRefPubMed
22.
23.
Shimizu J, Matsumoto M, Yamazaki E, Yasue M (2008) Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo) 48:227–230CrossRef
Metadata
Title
Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report
Authors
Pierre-Olivier Champagne
Thibault Passeri
Sebastien Froelich
Publication date
01-03-2019
Publisher
Springer Vienna
Published in
Acta Neurochirurgica / Issue 3/2019
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-018-03782-4

Other articles of this Issue 3/2019

Acta Neurochirurgica 3/2019 Go to the issue

Case Report - Vascular Neurosurgery - Ischemia

Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab

Original Article - Brain trauma

A case series of early and late cranioplasty—comparison of surgical outcomes

Original Article - Brain Tumors

Early postoperative MRI after resection of brain metastases—complete tumour resection associated with prolonged survival

Original Article - Brain Tumors

Stereotactic brain biopsy: evaluation of robot-assisted procedure in 60 patients

Case Report - Vascular Neurosurgery - Ischemia

Intracranial stenting after tumor exeresis complicated by delayed kinking of the middle cerebral artery

Editorial (by Invitation) - Tumor - Glioma

What a waste of MRI-scans!